MDUFA Negotiations Mellow Out Over Opposing Wish Lists
This article was originally published in Clinica
FDA and industry took a step back from active negotiations of new user-fee provisions at a recent meeting to examine the technical details and basic assumptions of some of the programs that have been identified for possible user-fee support when the program is reauthorized in 2017.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.